Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer

Final results from the randomised phase III TANIA trial in bevacizumab-pretreated metastatic breast cancer showed that although adding bevacizumab to second- and third-line chemotherapy significantly improved second-line progression-free survival (PFS) versus chemotherapy alone, third-line PFS and overall survival (secondary end points) were not significantly improved with continued bevacizumab.

from Cancer via ola Kala on Inoreader http://ift.tt/2aVN4Yg
via IFTTT